Access platform-led growth prospects ahead
12/09/2023
wheezo to access a larger addressable market
17/07/2023
Investor recap of Respiri's strategic focus
07/06/2023
Commercialisation at the forefront
28/04/2023
Wheezo commercialization picking up pace
29/03/2023
Strong momentum heading into FY24
01/03/2023
Dollars in the bank with CMS reimbursement
07/02/2023
NC rollout to expand wheezo market potential
09/01/2023
New funding to support commercial traction
03/01/2023
Sixth in spate of new client wins
20/12/2022
First primary care setting client win
07/12/2022
Commercialization efforts gathering steam
28/11/2022
Wheezo bags third client win in the US
18/11/2022
06/10/2022
Objective measures for better outcomes
22/09/2022
22/09/2022
wheezo® adoption momentum grows
29/11/2022
US Footprint Grows; Pipeline Full
22/08/2022
New codes boost US opportunity
06/12/2021
Wheezo receives FDA clearance in the US
29/03/2021
Manufacturing Efficiencies to Lift Margins
04/11/2020
Data-Driven Asthma Management as a Service
14/09/2020